ReviewNPJ Parkinson's disease2018
Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health.
Review in NPJ Parkinson's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 101 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Goal Management Training Home-Based Approach for Cognitive Impairment in Parkinson's Disease: A Single-Blind Randomized Trial
Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease
Who cites it
101 citing papers in PubMed, 4 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease.Age and ageing · 2026Guideline
- Dopaminergic Treatment and Episodic Memory in Parkinson's Disease: A Meta-analysis of the Literature.Neuropsychology review · 2025Pooled it
- Effects of fruit and vegetable intake on memory and attention: a systematic review of randomized controlled trials.Systematic reviews · 2024Pooled it
- Efficacy of virtual reality-based training programs and games on the improvement of cognitive disorders in patients: a systematic review and meta-analysis.BMC psychiatry · 2024Pooled it
- Boswellic acids as an adjunct therapy in Parkinson's disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers.Inflammopharmacology · 2025Trial
- Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease.Clinical and translational science · 2024Trial
- Trial
- Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development.Journal of Parkinson's disease · 2026Article
- Prevalence, predictors, and emerging biomarkers for cognitive impairment and neuropsychiatric manifestations in Parkinson's disease in Africa: A systematic review.Journal of Parkinson's disease · 2026Review
- A Comparison of Machine Learning Models for Classification of Parkinson's Disease During a Working Memory and Sustained Attention Task.Brain sciences · 2026Article
- A qualitative approach to extract diagnostic patterns of cognitive impairment in Parkinson's disease.Scientific reports · 2026Article
- Strategy Use Among People With Parkinson's Disease During the Weekly Calendar Planning Activity.The American journal of occupational therapy : official publication of the American Occupational Therapy Association · 2026Article
- Barriers and enablers to cognitive assessment in Parkinson's disease: A qualitative contextual inquiry.Journal of Parkinson's disease · 2026Article
- Clinical usability of telephone-based cognitive screening tests in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Effects of physical exercise on cognitive impairment in patients with Alzheimer's disease, Parkinson's disease or mild cognitive impairment: a systematic review and meta-analysis.European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity · 2026Review
- Motor-Derived Digital Biomarkers for Identifying Low-MoCA Status in People with Parkinson's Disease.Sensors (Basel, Switzerland) · 2026Article
- Recommendations to Improve Healthcare Service Provision for Cognitive Impairment in People With Parkinson's Disease: A Mixed Methods Study of the Lived Experience Expert Perspective.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Characteristics and mechanisms of cognitive impairment in Parkinson disease.Nature reviews. Neurology · 2026Review
- Targeting Oxidative Stress and Apoptosis with Levothyroxine in Experimental Parkinson's Disease in Rats.Neurochemical research · 2026Article
- Molecular mechanisms of exercise-induced neuroprotection against Parkinson's disease.Sports medicine and health science · 2026Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 15 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with Parkinson's disease (PD) and their care partners frequently report cognitive decline as one of their greatest concerns. Mild cognitive impairment affects approximately 20-50% of people with PD, and longitudinal studies reveal dementia in up to 80% of PD. Through the Parkinson's Disease Foundation Community Choice Research Award Program, the PD community identified maintaining cognitive function as one of their major unmet needs. In response, a working group of experts across multiple disciplines was organized to evaluate the unmet needs, current challenges, and future opportunities related to cognitive impairment in PD. Specific conference goals included defining the current state in the field and gaps regarding cognitive issues in PD from patient, care partner, and healthcare professional viewpoints; discussing non-pharmacological interventions to help maintain cognitive function; forming recommendations for what people with PD can do at all disease stages to maintain cognitive health; and proposing ideas for how healthcare professionals can approach cognitive changes in PD. This paper summarizes the discussions of the conference, first by addressing what is currently known about cognitive dysfunction in PD and discussing several non-pharmacological interventions that are often suggested to people with PD. Second, based on the conference discussions, we provide considerations for people with PD for maintaining cognitive health and for healthcare professionals and care partners when working with people with PD experiencing cognitive impairment. Furthermore, we highlight key issues and knowledge gaps that need to be addressed in order to advance research in cognition in PD and improve clinical care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.